[Cancer Management and Research] The prognostic values of overall survival and cancer-specific survival for bone sarcomas of the hands or feet were assessed using Cox proportional hazards regression model with univariate and multivariate analyses.
With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.
[OncoTargets and Therapy] This review examines the rationale of olaratumab in the treatment of advanced soft-tissue sarcomas and its emerging role in clinical practice.
Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.
Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.
Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.
After lymphodepletion in patients with advanced HER2+ sarcoma, T cells expanded in 5 of 6 patients who received infusions of HER2-CAR T cells.
In patients with soft tissue sarcoma pretreated with doxorubicin, treatment with regorafenib significantly reduced the risk of progression symptoms or toxicity.
Researchers indicate that it may be possible lower amputation rates by nearly 80% in patients with extremity sarcomas.
A drug currently used for hypertension may be effective for patients with soft tissue sarcoma, based on the finding of researchers in Europe.
In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.
The US FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma.
The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Two new compounds suppress tumor growth in cell culture and mouse xenograft models of Ewing sarcoma, a rare pediatric cancer. These 2 compounds are similar to mithramycin, also known as picamycin, a drug no longer manufactured due to its toxicity.
The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.
Among children with intermediate-risk rhabdomyosarcoma that is negative for a fusion gene, those who had a high score of the specific gene signature MG5 had poorer survival outcomes compared with those who had a low score of MG5.
The FDA has approved trabectedin (Yondelis) for treatment of unresectable or metastatic soft tissue sarcoma.
A large prospective postcommercialization study in patients with advanced STS in Europe confirmed the long-term anticancer activity of trabectedin (Yondelis) in different subtypes of sarcoma.
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
Mesenchymal chondrosarcoma, which often affects young adults, is among the deadliest cancers.
Adult patients with sarcoma experience significant symptom burden, which has a strong negative impact on health-related quality of life.
Data from a phase 2 trial supports continuation of trabectedin for patients with advanced soft-tissue sarcoma (STS) who have not progressed after six courses of treatment.
Image-guided radiotherapy can effectively treat soft tissue sarcomas in the extremities.
A combination of experimental drugs caused Ewing sarcoma tumors to disappear in mice.
A shoulder surgical aid, known as the Spider Limb Positioner, was adapted successfully to conduct a left hip disarticulation on a patient with melanoma.
Is pazopanib (Votrient) approved for the treatment of leiomyosarcoma?
A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.
Meeting the challenges of the significant morbidity, functional impairment, and alterations in body image in patients undergoing this surgical resection.
A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.
A new analysis confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. In addition, hemoglobin at baseline was found to be a new prognostic factor.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|